BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$344M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$266M |
| 3 |
Motorola Solutions
MSI
|
+$224M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$222M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$210M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$235M |
| 2 |
Alibaba
BABA
|
+$199M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$195M |
| 4 |
iShares MSCI Emerging Markets ETF
EEM
|
+$132M |
| 5 |
APC
Anadarko Petroleum
APC
|
+$122M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.31% |
| 2 | Financials | 6.96% |
| 3 | Consumer Discretionary | 5.46% |
| 4 | Healthcare | 4.97% |
| 5 | Industrials | 4.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3176
Beazer Homes USA
BZH
$874M
| $71.1K | ﹤0.01% |
4,775
+1,449
| +44% | +$17.5K |
|
3177
Prothena Corp
PRTA
$466M
| $71K | ﹤0.01% |
9,057
+1,885
| +26% | +$16.7K |
|
3178
BridgeBio Pharma
BBIO
$15.9B
| $70.8K | ﹤0.01% |
+3,298
| New | +$91.2K |
|
|
ALTA
3179
DELISTED
Altabancorp
ALTA
| $70.7K | ﹤0.01% |
2,500
-12
| -0.5% | -$341 |
|
|
OPB
3180
DELISTED
Opus Bank Common Stock
OPB
| $70.5K | ﹤0.01% |
3,240
+1,029
| +47% | +$21.8K |
|
|
EXPR
3181
DELISTED
Express, Inc.
EXPR
| $70.5K | ﹤0.01% |
1,025
-303
| -23% | -$14.9K |
|
|
OMN
3182
DELISTED
OMNOVA Solutions Inc.
OMN
| $70.4K | ﹤0.01% |
6,995
+1,599
| +30% | +$15.9K |
|
3183
Digimarc Corp
DMRC
$158M
| $70.4K | ﹤0.01% |
1,801
+478
| +36% | +$20.6K |
|
|
EIDX
3184
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $70.3K | ﹤0.01% |
1,955
+114
| +6% | +$4.45K |
|
|
PEI
3185
DELISTED
Pennsylvania Real Estate Investment Trust
PEI
| $70.3K | ﹤0.01% |
819
-43
| -5% | -$3.65K |
|
3186
CALL
Southwest Airlines
LUV
$22B
| $70.2K | ﹤0.01% |
13
-302
| -96% | -$15.8K |
|
|
STML
3187
DELISTED
Stemline Therapeutics, Inc.
STML
| $70K | ﹤0.01% |
6,729
+2,479
| +58% | +$32.4K |
|
|
CEO
3188
DELISTED
CNOOC Limited
CEO
| $70K | ﹤0.01% |
460
-1,163
| -72% | -$183K |
|
|
LGTY
3189
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
| $69.6K | ﹤0.01% |
4,636
+758
| +20% | +$10.7K |
|
3190
REX American Resources
REX
$1.44B
| $69.6K | ﹤0.01% |
5,472
+1,662
| +44% | +$20.6K |
|
|
EFC
3191
Ellington Financial
EFC
$1.76B
| $69.5K | ﹤0.01% |
3,845
+2,545
| +196% | +$45.2K |
|
|
HTB
3192
HomeTrust Bancshares
HTB
$837M
| $69.3K | ﹤0.01% |
2,658
-44
| -2% | -$1.12K |
|
3193
Red Robin
RRGB
$183M
| $69K | ﹤0.01% |
2,076
-150,220
| -99% | -$4.93M |
|
3194
Bally's
BALY
$660M
| $68.9K | ﹤0.01% |
3,018
+2,847
| +1,665% | +$70.1K |
|
3195
Twist Bioscience
TWST
$7.86B
| $68.8K | ﹤0.01% |
2,882
+2,315
| +408% | +$67.3K |
|
|
COWN
3196
DELISTED
Cowen Inc. Class A Common Stock
COWN
| $68.5K | ﹤0.01% |
4,453
-470
| -10% | -$7.63K |
|
3197
Wave Life Sciences
WVE
$1.02B
| $68.3K | ﹤0.01% |
3,329
+1,067
| +47% | +$24.5K |
|
|
PGNX
3198
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $68.1K | ﹤0.01% |
13,467
+4,142
| +44% | +$20.7K |
|
3199
Arrow Financial
AROW
$723M
| $68K | ﹤0.01% |
2,294
-49
| -2% | -$1.41K |
|
3200
TG Therapeutics
TGTX
$7.34B
| $67.8K | ﹤0.01% |
12,071
+5,099
| +73% | +$35.5K |
|
Similar funds
BNP Paribas Financial Markets's Q3 2019 Portfolio in Review
As of Q3 2019, BNP Paribas Financial Markets held 4,631 positions worth $56.3B, up 12% from $50.2B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
BNP Paribas Financial Markets deployed $1.76B of net new capital in Q3 2019, opening 103 new positions and adding to 2,522 existing holdings. Its largest new stake was VanEck Pharmaceutical ETF: 400,000 shares worth $22.8M.
By sector, the portfolio is most concentrated in Technology at 8.3% of assets, down from 8.5% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $235M trimmed.
- BNP Paribas Financial Markets's largest Q3 2019 buy was VanEck Pharmaceutical ETF: 400,000 shares worth $22.8M.
- BNP Paribas Financial Markets added most to Visa in Q3 2019, an estimated $344M increase.
- BNP Paribas Financial Markets's biggest Q3 2019 reduction was Apple, cutting an estimated $235M.
- BNP Paribas Financial Markets fully exited Anadarko Petroleum in Q3 2019, selling an estimated $122M.
- BNP Paribas Financial Markets's ten largest holdings make up 15% of its $56.3B portfolio in Q3 2019.
- BNP Paribas Financial Markets opened 103 new positions and closed 116 in Q3 2019.
- BNP Paribas Financial Markets's portfolio value rose 12% quarter-over-quarter to $56.3B.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2019, filed 7 Nov 2019.